异上腺素修改型聚乙烯胺作为一种有效的基因传递系统,用于喘治疗和呼吸道重塑抑制
Jiwon An1, Moonhwan Choi1, Sol Kim1
1Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04763, Korea.
Biomaterials research
|February 3, 2025
概括
一种新的基因传递系统,PEI-异上腺素,通过有效地将siRNA传递到目标细胞,显示出对喘治疗的希望. 这种系统减少了气道炎症,纤维化和高反应,为治疗气道重塑提供了潜在的进步.
科学领域:
- 生物医学工程 生物医学工程
- 基因治疗 基因治疗
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘治疗和呼吸道改造需要有效的基因传递系统.
- 针对ADRB2等特定受体对于改善治疗结果至关重要.
- 现有的基因传递载体往往缺乏足够的效率和特异性.
研究的目的:
- 开发和评估一种新型的基因传递系统,用异上腺素 (PEI-异上腺素) 修改的聚乙烯胺,用于喘中的向基因传递.
- 在体外和体内评估PEI-异上综合体的生物相容性,传染效率和治疗疗效.
- 研究该系统在减少呼吸道炎症,纤维化和高反应性方面的潜力.
主要方法:
- 使用Beas2B和THP-1细胞进行体外研究,以评估PEI-异上腺素复合体与siRNA的生物相容性和转染效率.
- 在活体研究中,使用一种小鼠慢性喘模型来评估向ADRB2表达细胞的基因传递.
- 对支气管液和肺组织进行分析,以量化治疗效果,包括减少炎症细胞,纤维化和基因表达 (Arg1).
主要成果:
- 在基于细胞的测定中,PEI-异上显示出优异的生物相容性和安全性.
- 该siRNA/PEI-异上腺素复合物实现了80%的递送率,在向ADRB2表达细胞方面明显优于聚乙烯胺2K (20%).
- 在体内观察到呼吸道炎症细胞,纤维化和阿基因酶-1基因表达的显著减少 (63%的减少).
- 该系统有效地抑制了气道过度响应.
结论:
- PEI-异上腺素是用于喘治疗的高效和生物相容的基因输送系统.
- 该系统显示了针对性基因的显著潜力,如阿尔金纳-1,以减轻呼吸道炎症和纤维化.
- 这种新的方法为推进喘治疗和管理呼吸道疾病的气道改造提供了一个有希望的策略.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
233
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
233
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
01:17Drugs Used in Lower Respiratory Disorders: Overview
344
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
344
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
01:30Adrenergic Agonists: Therapeutic Uses
722
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
722
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231